Neurogene, Inc.
May 7, 2024
Neurogene announced initial safety and tolerability data from its Rett gene therapy clinical. NGN-401 was generally well-tolerated by all three patients dosed, with follow-up of approximately 9, 6 and 3 months post-dosing. These data were presented during the American Society of Gene and Cell ...